Table 1.
Variable | N=28 | (%) | Variable | N=28 | (%) |
---|---|---|---|---|---|
Mean age, years (SD) | 69.3 | (±9.8) | Medication use | ||
Race/ethnicity | Short-acting B-agonist | 28 | 100 | ||
White | 26 | 92.9 | Short-acting anticholinergic | 22 | 78.6 |
African American | 2 | 7.1 | Long-acting B-agonist | 19 | 67.9 |
Current smoker | 5 | 17.9 | Long-acting anticholinergic | 5 | 17.9 |
Chronic bronchitisa | 15 | 53.6 | Inhaled steroidd | 22 | 78.6 |
Chronic respiratory symptoms | Theophylline | 2 | 7.1 | ||
Dyspnea | 26 | 92.9 | Medications used to treat in last 12 months | ||
Cough | 13 | 46.4 | |||
Wheeze | 17 | 69.7 | ≥1 Prednisone course | 8 | 28.6 |
Sputum production | 9 | 32.1 | ≥1 Antibiotic course | 8 | 28.6 |
Mean pack-years (SD) | 52.0 | (±30.9) | ≥1 Prednisone or antibiotic | 13 | 46.4 |
Mean FEV1 in liters (SD)b | 1.6 | (±0.5) | COPD health care utilization in last 12 months | ||
Mean FEV1 % predictedb | 45.6 | (±13.3) | |||
GOLD stage | ED visits | 6 | 21.4 | ||
II – Moderate | 12 | 42.9 | Hospitalizations | 1 | 3.6 |
III – Severe | 12 | 42.9 | Hospitalization or ED visit | 6 | 21.4 |
IV – Very severe | 4 | 14.3 | |||
Home oxygen usec | 7 | 25 |
Notes:
N=1 missing.
Postbronchodilator except for one patient with missing value for which the prebronchodilator value was used.
As reported by the patient.
Flunisolide, triamcinolone, and mometasone.
Abbreviations: SD, standard deviation; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ED, Emergency Department.